Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zai Lab Ltd ADR
(NQ:
ZLAB
)
16.17
+0.05 (+0.31%)
Streaming Delayed Price
Updated: 11:44 AM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Ltd ADR
< Previous
1
2
3
4
Next >
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
January 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
January 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
January 03, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in January Investor Conferences
December 20, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
December 15, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
December 05, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
November 09, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2022
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
November 08, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
October 31, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 18, 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Launches its first Trust Report
October 14, 2022
Outlines Company’s ESG Strategy through its Trust for Life Commitments
From
Zai Lab Limited
Via
GlobeNewswire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
September 27, 2022
From
Seagen Inc.
Via
Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
June 03, 2022
From
Novocure
Via
Business Wire
Zai Lab Limited (NASDAQ: ZLAB) Investor Alert: Investigation over Possible Violations of Securities Laws
April 25, 2022
San Diego, CA -- (SBWIRE) -- 04/25/2022 -- Zai Lab Limited is under investigation over potential securities laws violations by Zai Lab Limited in connection with certain financial statements.
Via
SBWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
April 04, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
April 01, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLAB
March 31, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Promising Developments in Breast Cancer Treatments Ahead in 2022
January 12, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...
Via
FinancialNewsMedia
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
November 09, 2021
From
PureTech Health plc
Via
Business Wire
Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients
October 21, 2021
From
Crescendo Biologics Ltd
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.